Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

David Wyles

Concepts (241)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
59
2025
740
11.800
Why?
Hepatitis C, Chronic
32
2025
164
9.350
Why?
Hepacivirus
48
2025
258
8.650
Why?
Hepatitis C
29
2025
263
8.320
Why?
Benzimidazoles
16
2020
169
4.300
Why?
Drug Resistance, Viral
18
2025
115
4.100
Why?
Coinfection
15
2020
137
3.060
Why?
HIV Infections
28
2022
2830
3.050
Why?
Ribavirin
15
2020
91
2.370
Why?
Sofosbuvir
16
2022
59
2.300
Why?
Quinoxalines
7
2019
66
2.280
Why?
Fluorenes
7
2020
42
2.250
Why?
Sulfonamides
13
2020
513
2.250
Why?
Viral Nonstructural Proteins
10
2025
65
2.190
Why?
Liver Cirrhosis
8
2020
316
2.160
Why?
Drug Therapy, Combination
26
2020
1060
1.840
Why?
Uridine Monophosphate
5
2016
15
1.700
Why?
Carbamates
9
2020
49
1.480
Why?
Anti-Retroviral Agents
5
2019
235
1.450
Why?
Protease Inhibitors
10
2020
107
1.390
Why?
Hepatitis B, Chronic
3
2019
24
1.350
Why?
Proline
11
2020
80
1.270
Why?
Pyrrolidines
9
2019
80
1.210
Why?
Genotype
21
2025
1920
1.200
Why?
Congresses as Topic
3
2021
233
1.180
Why?
Sustained Virologic Response
11
2025
40
1.160
Why?
Hepatitis, Viral, Human
3
2021
26
1.160
Why?
Cyclopropanes
11
2020
90
0.980
Why?
Drug Users
2
2024
41
0.970
Why?
Lactams, Macrocyclic
10
2020
49
0.910
Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
21
0.810
Why?
HIV-1
8
2020
863
0.790
Why?
Treatment Failure
6
2025
353
0.750
Why?
Virus Replication
7
2012
480
0.740
Why?
Disease Eradication
1
2020
5
0.700
Why?
Organophosphonates
4
2011
92
0.690
Why?
Homosexuality, Male
2
2021
182
0.680
Why?
RNA, Viral
9
2025
653
0.670
Why?
Humans
77
2025
137514
0.660
Why?
Anti-HIV Agents
6
2020
775
0.650
Why?
Valine
7
2020
82
0.640
Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.560
Why?
Imidazoles
2
2015
244
0.540
Why?
Ritonavir
6
2020
73
0.540
Why?
Middle Aged
32
2025
33355
0.540
Why?
Darunavir
1
2017
18
0.540
Why?
Aminoisobutyric Acids
5
2019
7
0.520
Why?
Uracil
5
2020
31
0.510
Why?
Antiretroviral Therapy, Highly Active
3
2015
272
0.500
Why?
Male
41
2025
67718
0.490
Why?
Leucine
5
2019
111
0.490
Why?
Treatment Outcome
18
2023
10821
0.490
Why?
Anilides
5
2020
73
0.490
Why?
Education, Medical, Continuing
1
2016
126
0.470
Why?
Adult
31
2025
37821
0.460
Why?
Biomedical Research
1
2021
689
0.450
Why?
Adenine
4
2020
268
0.450
Why?
Female
39
2025
73162
0.440
Why?
Oligopeptides
2
2013
273
0.440
Why?
Viral Load
7
2020
462
0.430
Why?
Pyridazines
1
2014
56
0.430
Why?
2-Naphthylamine
5
2020
7
0.420
Why?
Macrocyclic Compounds
3
2019
9
0.420
Why?
Purines
1
2014
176
0.410
Why?
Quinolines
1
2014
180
0.400
Why?
Replicon
3
2009
14
0.400
Why?
Liver
1
2021
1940
0.390
Why?
Scavenger Receptors, Class B
1
2012
14
0.380
Why?
Disease Management
1
2016
625
0.380
Why?
Aged
17
2024
23798
0.350
Why?
Mass Screening
4
2025
1264
0.350
Why?
Retreatment
2
2021
72
0.340
Why?
Drug Synergism
3
2008
379
0.330
Why?
Acquired Immunodeficiency Syndrome
2
2020
233
0.300
Why?
Dideoxynucleosides
2
2005
21
0.290
Why?
Liver Diseases
2
2016
313
0.290
Why?
Interferon-alpha
4
2013
198
0.280
Why?
Cytokines
1
2015
2095
0.270
Why?
Amino Acid Substitution
2
2018
309
0.260
Why?
Cytosine
2
2009
49
0.260
Why?
Global Health
2
2020
386
0.250
Why?
Hepatitis B virus
2
2019
40
0.230
Why?
HIV
2
2019
233
0.230
Why?
Herpes Simplex
1
2005
93
0.230
Why?
Hepatitis
1
2004
48
0.230
Why?
Alanine
2
2021
153
0.210
Why?
Prevalence
3
2019
2719
0.200
Why?
Interferons
2
2015
199
0.200
Why?
Mutation, Missense
3
2014
338
0.190
Why?
Hospitals
2
2024
678
0.190
Why?
Interferon beta-1a
1
2021
12
0.190
Why?
Young Adult
10
2019
13243
0.190
Why?
Feasibility Studies
1
2025
950
0.180
Why?
Hepatitis A
1
2021
26
0.180
Why?
Phylogeny
1
2025
898
0.180
Why?
Adenosine Monophosphate
1
2021
66
0.180
Why?
Tenofovir
2
2020
240
0.180
Why?
Hepatitis B
1
2021
71
0.170
Why?
World Health Organization
1
2020
122
0.170
Why?
Disease Progression
2
2019
2755
0.160
Why?
Data Interpretation, Statistical
2
2018
352
0.160
Why?
Polyethylene Glycols
2
2015
640
0.150
Why?
Emergency Service, Hospital
3
2025
2054
0.150
Why?
Esters
2
2009
77
0.150
Why?
United States
10
2025
14696
0.150
Why?
CD4 Lymphocyte Count
2
2017
270
0.150
Why?
Ribosomes
2
2010
174
0.150
Why?
Immunologic Factors
1
2020
239
0.150
Why?
Nucleic Acid Conformation
4
2014
720
0.140
Why?
Hospitalization
2
2024
2197
0.140
Why?
Alanine Transaminase
1
2018
158
0.130
Why?
DNA, Viral
1
2019
362
0.130
Why?
Genes, Viral
1
2016
88
0.130
Why?
DNA Mutational Analysis
1
2018
401
0.130
Why?
Molecular Structure
2
2008
508
0.120
Why?
Mutation
2
2018
3964
0.120
Why?
Survival Analysis
1
2019
1320
0.120
Why?
Patient Compliance
1
2020
586
0.120
Why?
High-Throughput Nucleotide Sequencing
2
2016
538
0.120
Why?
Adolescent
5
2022
21555
0.120
Why?
Dose-Response Relationship, Drug
2
2017
2066
0.120
Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
19
0.110
Why?
AIDS-Related Opportunistic Infections
1
2015
125
0.110
Why?
Opiate Substitution Treatment
1
2016
147
0.110
Why?
Chemokines
1
2015
229
0.110
Why?
Risk Assessment
2
2025
3439
0.110
Why?
Chemokine CXCL10
1
2014
39
0.110
Why?
Drug Interactions
1
2015
409
0.110
Why?
Phenylenediamines
1
2013
10
0.110
Why?
Prospective Studies
5
2025
7598
0.110
Why?
Fibrosis
1
2016
552
0.110
Why?
Viral Proteins
2
2014
346
0.100
Why?
Prognosis
2
2019
4031
0.100
Why?
Microbial Sensitivity Tests
2
2012
362
0.100
Why?
Drug Combinations
3
2019
344
0.100
Why?
Quality of Life
1
2025
2870
0.100
Why?
Drug Discovery
1
2013
141
0.090
Why?
Administration, Oral
1
2014
814
0.090
Why?
Mental Disorders
1
2020
1083
0.090
Why?
Cohort Studies
5
2024
5730
0.090
Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
252
0.090
Why?
Case-Control Studies
2
2017
3546
0.090
Why?
Telemedicine
1
2020
852
0.090
Why?
Prodrugs
1
2011
49
0.090
Why?
Models, Molecular
3
2012
1586
0.090
Why?
Nucleosides
1
2010
27
0.090
Why?
Riboswitch
1
2012
67
0.080
Why?
Japan
2
2021
116
0.080
Why?
Drug Administration Schedule
3
2017
784
0.080
Why?
Cell Line, Tumor
2
2008
3420
0.080
Why?
Drug Design
1
2010
170
0.080
Why?
Biomarkers
1
2020
4172
0.080
Why?
Cell Line
2
2012
2852
0.080
Why?
Piperidines
1
2010
208
0.070
Why?
Phenylthiourea
1
2008
5
0.070
Why?
Body Mass Index
1
2017
2369
0.070
Why?
Practice Guidelines as Topic
1
2016
1580
0.070
Why?
Immunity, Innate
1
2014
832
0.070
Why?
Plasmids
1
2009
363
0.070
Why?
Structure-Activity Relationship
1
2009
586
0.070
Why?
Inhibitory Concentration 50
1
2006
90
0.070
Why?
Luciferases
1
2006
151
0.060
Why?
Genes, Reporter
1
2006
268
0.060
Why?
Thailand
1
2025
17
0.060
Why?
Saquinavir
1
2004
1
0.060
Why?
Simplexvirus
1
2005
80
0.060
Why?
Indinavir
1
2004
7
0.060
Why?
Uganda
1
2025
72
0.060
Why?
Nelfinavir
1
2004
9
0.060
Why?
Drug Labeling
1
2005
40
0.060
Why?
Nevirapine
1
2004
17
0.060
Why?
Oxazines
1
2004
30
0.060
Why?
Pandemics
2
2024
1619
0.060
Why?
Benzoxazines
1
2004
31
0.060
Why?
Lopinavir
1
2004
30
0.060
Why?
Brazil
1
2025
167
0.060
Why?
Alkynes
1
2004
56
0.060
Why?
Zidovudine
1
2004
78
0.060
Why?
Time Factors
1
2015
6817
0.060
Why?
Liver Function Tests
1
2004
114
0.060
Why?
Reverse Transcriptase Inhibitors
1
2004
84
0.060
Why?
South Africa
1
2025
219
0.060
Why?
Transfection
1
2006
948
0.060
Why?
Pregnancy
1
2017
6745
0.050
Why?
Bone Marrow Transplantation
1
2005
286
0.050
Why?
Pyrimidinones
1
2004
114
0.050
Why?
Recombinant Fusion Proteins
1
2006
665
0.050
Why?
Carcinoma, Hepatocellular
1
2006
360
0.050
Why?
Double-Blind Method
2
2021
1987
0.050
Why?
Polyphosphates
1
2022
36
0.050
Why?
Singapore
1
2021
22
0.050
Why?
Republic of Korea
1
2021
36
0.050
Why?
Dried Blood Spot Testing
1
2022
103
0.050
Why?
Mexico
1
2021
220
0.040
Why?
Retrospective Studies
5
2019
15628
0.040
Why?
Protein Biosynthesis
2
2014
434
0.040
Why?
Liver Neoplasms
1
2006
786
0.040
Why?
Raltegravir Potassium
1
2019
17
0.040
Why?
Clinical Trials, Phase II as Topic
1
2019
75
0.040
Why?
Clinical Trials, Phase III as Topic
1
2019
105
0.040
Why?
Intensive Care Units
1
2024
803
0.040
Why?
Drug Resistance, Multiple, Viral
1
2017
11
0.030
Why?
Longitudinal Studies
1
2024
2857
0.030
Why?
Kinetics
1
2020
1679
0.030
Why?
Oxygen
1
2021
943
0.030
Why?
Medicaid
1
2020
436
0.030
Why?
Program Evaluation
1
2020
892
0.030
Why?
Incidence
2
2013
2792
0.030
Why?
RNA
1
2022
924
0.030
Why?
Cell-Free System
1
2014
53
0.030
Why?
Hepatitis C Antibodies
1
2014
11
0.030
Why?
Spain
1
2014
41
0.030
Why?
Enzyme-Linked Immunosorbent Assay
1
2016
849
0.030
Why?
Polymorphism, Genetic
1
2017
658
0.030
Why?
Patient Acceptance of Health Care
1
2020
809
0.030
Why?
Patient Care
1
2014
111
0.030
Why?
Aged, 80 and over
2
2019
7593
0.030
Why?
Patient Reported Outcome Measures
1
2017
403
0.030
Why?
Withholding Treatment
1
2013
76
0.030
Why?
Risk Factors
2
2020
10356
0.030
Why?
Early Diagnosis
1
2014
244
0.030
Why?
Plasma
1
2014
213
0.020
Why?
Fluorescence Resonance Energy Transfer
1
2012
177
0.020
Why?
Virus Internalization
1
2010
47
0.020
Why?
Ligands
1
2012
665
0.020
Why?
Recombinant Proteins
1
2013
1357
0.020
Why?
Pilot Projects
1
2015
1703
0.020
Why?
Magnesium
1
2009
159
0.020
Why?
Lamivudine
1
2009
64
0.020
Why?
Genome, Viral
1
2009
144
0.020
Why?
Referral and Consultation
1
2014
780
0.020
Why?
Logistic Models
1
2013
2064
0.020
Why?
Phenotype
1
2014
3205
0.020
Why?
Base Sequence
1
2009
2180
0.020
Why?
Severity of Illness Index
1
2013
2838
0.020
Why?
Randomized Controlled Trials as Topic
1
2011
1465
0.010
Why?
Mice, Transgenic
1
2009
2182
0.010
Why?
Animals
2
2018
37011
0.010
Why?
Substance-Related Disorders
1
2011
1079
0.010
Why?
Signal Transduction
1
2009
5096
0.010
Why?
Mice
1
2009
17843
0.010
Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)